


Specially Appointed Assistant Professor Shizuka ISHITANI

We are currently testing the therapeutic efficacy of the X inhibitor in mouse models of polyglutamine diseases and further modifying its structure to improve its properties as a drug. We hope that this project will lead to the development of definitive therapies for polyglutamine disease.



Marketability and challenges in development: Polyglutamine disease is a genetic disorder, for which only symptomatic treatment currently exists. Therefore, it is expected to develop a curative medicine that prevents the onset of the disease or suppresses the progression of symptoms.